Regeneron (REGN) Price Target Hits $1,057 as BMO and Canaccord Lift Forecasts on Dupixent Growth
Published: December 4, 2025 Key Takeaways Wall Street Re‑rates Regeneron After Big Run — and Bigger Dupixent Story Regeneron Pharmaceuticals has suddenly become one of the most hotly debated large‑cap biotechs on Wall Street. On Thursday, December 4, 2025, multiple
